Published in Hepatitis Weekly, August 11th, 2008
"A total of 26 naive patients histologically confirmed to have chronic hepatitis C were double-blindly and randomly assigned to receive either IFN beta-1a 44 mu g (12 MIU) (IFN beta-1a group) or placebo (placebo group) three times per week for 12 weeks. At...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.